Search
laquinimod
Indications:
- relapsing-remitting multiple sclerosis (investigational)
Dosage:
- 0.6 mg PO QD
Adverse effects:
- slightly more common than placebo
- back pain
- GI symptoms
- cough
- minor infections
- urinary tract infection
- sinusitis
- elevated serum AST, serum ALT (1%)
Mechanism of action:
- anti-inflammatory properties
General
quinolone
neurologic agent
Database Correlations
PUBCHEM correlations
References
- Journal Watch, Massachusetts Medical Society, March 15, 2012
Comi G et al.
Placebo-controlled trial of oral laquinimod for multiple
sclerosis.
N Engl J Med 2012 Mar 15; 366:1000
PMID: 22417253